Get the Stockscreener App
4.30
0.94%
0.04
Savara Inc stock is traded at $4.30, with a volume of 1.22M.
It is up +0.94% in the last 24 hours and up +27.22% over the past month.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
See More
Previous Close:
$4.26
Open:
$4.32
24h Volume:
1.22M
Relative Volume:
0.77
Market Cap:
$743.20M
Revenue:
-
Net Income/Loss:
$-54.70M
P/E Ratio:
-13.03
EPS:
-0.33
Net Cash Flow:
$-51.36M
1W Performance:
+8.86%
1M Performance:
+27.22%
6M Performance:
+43.81%
1Y Performance:
+34.80%
1-Day Range:
$4.21
$4.38
1-Week Range:
$3.945
$4.40
52-Week Range:
$1.89
$4.505
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
4.30 | 866.77M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Savara Stock: A High-Risk Opportunity (NASDAQ:SVRA) - Seeking Alpha
Savara Inc. stock momentum explainedTrade Risk Assessment & Smart Allocation Stock Tips - newser.com
Savara (NASDAQ:SVRA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Multi asset correlation models including Savara Inc.July 2025 Weekly Recap & High Accuracy Investment Signals - newser.com
What Fibonacci levels say about Savara Inc. reboundEarnings Beat & Stock Portfolio Risk Control - newser.com
Is Savara Inc. stock attractive for income investorsJuly 2025 Levels & Reliable Breakout Forecasts - newser.com
Volatility clustering patterns for Savara Inc.Trend Reversal & Daily Volume Surge Signals - newser.com
Savara (NASDAQ:SVRA) Stock Price Expected to Rise, Oppenheimer Analyst Says - MarketBeat
Short interest data insights for Savara Inc.Trade Volume Summary & Fast Entry High Yield Tips - newser.com
Is Savara Inc. (YB4P) stock supported by free cash flowPortfolio Growth Summary & Weekly Top Gainers Trade List - newser.com
Oppenheimer Raises Price Target for Savara (SVRA) to $9.00 | SVR - GuruFocus
Citizens Jmp Cuts Savara (NASDAQ:SVRA) Price Target to $10.00 - MarketBeat
Oppenheimer Adjusts Price Target on Savara to $9 From $8, Maintains Outperform Rating - MarketScreener
Assessing Savara (SVRA) Valuation Following Recent Share Price Momentum - Yahoo Finance
Savara (NASDAQ:SVRA) Posts Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Evaluating Savara Inc. with trendline analysisGap Down & Risk Adjusted Buy and Sell Alerts - newser.com
Savara Banks Cash As Analysts Stay Upbeat On New Drug - Finimize
Citizens Lowers Price Target for Savara (SVRA) but Maintains Rat - GuruFocus
Citizens lowers Savara stock price target to $10 on dilution concerns - Investing.com Nigeria
Savara Reports Third Quarter 2025 Financial Results and Provides Business Update - BioSpace
SVRA Bolsters Financial Position and Plans Key Submissions for M - GuruFocus
Savara Inc. Grants Equity Awards to New Employees - MSN
Savara Secures $75 Million Royalty Deal to Back Potential MOLBREEVI Launch - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Savara Inc. (SVRA) And Encourages Investors to Reach Out - ACCESS Newswire
SAVARA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Savara Stockholders to ... - Black Hills Pioneer
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Savara Inc.(SVRA) Shareholders - Sahm
Reviewing Savara (NASDAQ:SVRA) & Guardian Pharmacy Services (NYSE:GRDN) - Defense World
Levi & Korsinsky Announces the Filing of a Securities Class Acti - GuruFocus
Shareholders SueWallSt in New Class Action Against Savara Inc.Act Now - Nasdaq
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara - MarketScreener
Savara Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Savara Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsSVRA - MarketScreener
Investor Alert: Deadline Approaching to Join Savara Inc. (SVRA) Class ActionContact Levi & Korsinsky - Stockhouse
Levi & Korsinsky Helps Shareholders SueWallSt After Savara Inc. Stock Drops - ACCESS Newswire
Shareholders that lost money on Savara Inc.(SVRA) should contact Levi & Korsinsky about ... - Bluefield Daily Telegraph
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):